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Single-cell RNA sequencing (scRNA-seq) has
emerged as a powerful tool for resolving transcrip-
tional heterogeneity. However, its application to
studying cancerous tissues is currently hampered
by the lack of coverage across keymutation hotspots
in the vast majority of cells; this lack of coverage pre-
vents the correlation of genetic and transcriptional
readouts from the same single cell. To overcome
this, we developed TARGET-seq, a method for the
high-sensitivity detection ofmultiplemutationswithin
single cells from both genomic and coding DNA, in
parallel with unbiased whole-transcriptome analysis.
Applying TARGET-seq to 4,559 single cells, we
demonstrate how this technique uniquely resolves
transcriptional and genetic tumor heterogeneity in
myeloproliferative neoplasms (MPN) stem and pro-
genitor cells,providing insights intoderegulatedpath-
ways ofmutant and non-mutant cells. TARGET-seq is
a powerful tool for resolving the molecular signatures
of genetically distinct subclones of cancer cells.
INTRODUCTION
Resolving intratumoral heterogeneity (ITH) is critical for our un-
derstanding of tumor evolution and resistance to therapies;
this understanding, in turn, is required for the development of
effective cancer treatments and biomarkers for precision medi-
cine (McGranahan and Swanton, 2017). The best-characterizedMolecular Cell 73, 1–14,
This is an open access article undsource of ITH has been at the genetic level; this heterogeneity
has been identified through advances in next-generation
sequencing (NGS) techniques at the bulk and single-cell levels
(Vogelstein et al., 2013). However, certain factors beyond so-
matic mutations contribute to ITH. For example, some tumors
are hierarchically organized and contain cancer stem cells
(CSCs), which propagate disease relapse. The genetic events
underlying tumor evolution originate in CSCs, which in some tu-
mors are rare within the total tumor bulk population (Clevers,
2011; Magee et al., 2012; Woll et al., 2014). Furthermore, the
CSCs’ normal cellular counterparts, which lack genetic muta-
tions, can be difficult to distinguish frommalignant cells because
they might share phenotypic features, but these cells can never-
theless be informative for disease biology (Giustacchini et al.,
2017). Consequently, resolving ITH requires methods that allow
these multiple layers of heterogeneity to be teased apart.
A potentially powerful approach for gaining a better under-
standing of the functional consequences of ITH is to link genetic
ITH with the transcriptional signatures of distinct subpopulations
of tumor cells. A number of studies have begun to apply single-
cell RNA sequencing (scRNA-seq) to characterize different ma-
lignancies, demonstrating the power of scRNA-seq to identify
the different cell types that are encompassed within a
tumor, including cells with ‘‘stemness’’ signatures and charac-
terization of developmental hierarchies of tumor cells (Patel
et al., 2014; Tirosh et al., 2016a, 2016b; Venteicher et al.,
2017). However, although scRNA-seq approaches can readily
resolve such transcriptional heterogeneity, current techniques
do not allow parallel mutational analysis because of a lack of
coverage across mutation hotspots (Kiselev et al., 2017; Patel
et al., 2014; Tirosh et al., 2016b). This integration of mutational
and transcriptional information is crucial for linking genetic
evolution events to the cell of origin; this is of considerableMarch 21, 2019 ª 2019 The Author(s). Published by Elsevier Inc. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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within distinct and developmentally ordered stem and progenitor
cell types, as described in acute leukemia (Jan et al., 2012).
Furthermore, mutation analysis is also important for unravelling
disrupted gene expression in non-mutant cells; this disruption
of gene expression might be cell-extrinsically mediated and of
clinical importance (Giustacchini et al., 2017). In order to over-
come this current limitation in single-cell genomic techniques,
we set out to develop a method that combines full-length
scRNA-seq or 30-end-counting, high-throughput scRNA-seq
with high-sensitivity mutation analysis.
DESIGN
The limitation of applying current scRNA-sequencing techniques
to the detection of mutations in single cells partly relates to
the fact that commonly used ‘‘end-counting’’ scRNA-seq tech-
niques only detect the 30 or 50 region of transcripts (Hedlund
and Deng, 2018). Consequently, most mutations within the
body of a gene are not covered by sequencing reads. However,
scRNA-seq techniques that amplify full-length transcripts, such
as Smart-seq2 (Picelli et al., 2013), also have very poor sensitivity
with regard to detecting the expression of most genes in most
cells (Figure S1), and this difficulty precludes high-sensitivity
mutational analysis. Furthermore, the vast majority of mutations
identified in cancer are single-nucleotide variants (SNVs) and
small indels (Vogelstein et al., 2013); these might be either het-
erozygous or associated with loss of heterozygosity (LOH) and
have important functional consequences (Kharazi et al., 2011).
Therefore, a key challenge in the field is to minimize allelic drop-
outs (ADOs) in order to ensure the detection of both alleles from a
single cell.
It remains unclear whether the high ADO rates and lack of
coverage acrossmutation hotspots in scRNA-seq data is primar-
ily due to technical dropouts related to inefficient reverse tran-
scription (RT) and/or PCR amplification or whether they are the
result of true biological heterogeneity in the expression of mutant
transcripts across single cells. We therefore first optimized the
Smart-seq2 RT and PCR enzymatic conditions (SMART-seq+;
TableS1A); this resulted in a significant reduction in dropout rates
(Figure S1A), particularly for genes expressed at a low level (Fig-
uresS1BandC); a 25% increase in the number of genesdetected
per cell (Figure S1D); and a reduction in library bias (Figure S1E).
However, despite improved sensitivity for the detection of gene
expression with SMART-seq+, ADO rates remained exceedingly
high for most genes (Figures S1F–H), a fact that currently pre-
cludes reliable mutational analysis using scRNA-seq (Povinelli
et al., 2018). We therefore concluded that, because of the sto-
chastic nature of gene expression in single cells, improving sensi-
tivity for the analysis of coding DNA (cDNA) alone is unlikely to
provide sufficient sensitivity for the detection of most cancer-
associated mutations at the single-cell level.
Overcoming this problem requires the detection of mutations
from genomic DNA (gDNA) in parallel with cDNA. Techniques
for studying gDNA and mRNA from the same single cell have
been previously described. However, these techniques either
require both types of molecules to be physically separated
(Han et al., 2018; Hou et al., 2016; Macaulay et al., 2015), which2 Molecular Cell 73, 1–14, March 21, 2019inevitably results in some loss of genetic material and conse-
quently limits the techniques’ sensitivity, or they rely on the par-
allel amplification of total gDNA and mRNA followed by the
masking of coding regions (Dey et al., 2015). These technical
constraints restrict the sensitivity of such techniques for the
confident detection of specific point mutations. Whole-genome
amplification also introduces significant expense to the method
and has inherently high ADO and false-positive rates (Hosokawa
et al., 2017;Wang et al., 2014). As a result, up to now, these tech-
niques have not been widely used for parallel mutation or
scRNA-seq analysis in cancer. Methods that combine targeted
single-cell gene expression and mutation analysis have also
been reported (Cheow et al., 2016; Wang et al., 2017), but these
approaches have the limitation that only the expression of a
limited number of pre-selected genes can be analyzed per cell.
Recently, we have described a method for the high-sensitivity
detection of BCR-ABL1 (breakpoint cluster region and Abelson
murine leukemia viral oncogene homolog 1 fusion protein) tran-
scripts in parallel with scRNA-seq in chronic myeloid leukemia
stem cells (Giustacchini et al., 2017). Although this study high-
lights the power of linking mutation and transcriptome informa-
tion in single cells, the method is dependent on the expression
of the targeted gene and/or allele in all mutated cells. This
approach was effective in the specific case of the BCR-ABL
fusion gene. However, for many autosomal genes, expression
is undetectable or highly allelic-biased in the majority of tran-
scriptionally active andhighly proliferative K562 cells (FigureS1F)
and also in quiescent LinCD34+CD38 primary human hemato-
poietic stem and progenitor cells (HSPCs; Figures S1G and H);
this makes this method unsuitable to profile most mutations
found in cancer. Moreover, this approach precludes analysis of
non-coding mutations with key roles in tumorigenesis (Khurana
et al., 2016). We therefore developed a method named
TARGET-seq, which dramatically reduces ADOand also enables
the efficient detection of non-coding mutations from the same
single cell by allowing parallel, targeted mutation analysis of
gDNA and cDNA alongside scRNA-seq.
RESULTS
TARGET-Seq Dramatically Increases the Sensitivity of
Mutation Detection in Single Cells
In order to improve the detection of specific mRNA and gDNA
amplicons, we extensively modified previously published tem-
plate-switching protocols (Hedlund and Deng, 2018; Picelli
et al., 2013; Zheng et al., 2018). To improve the release of
gDNA, we modified the lysis procedure to include a mild prote-
ase digestion (Figure 1A and Table S1); we subsequently heat-
inactivated the protease to avoid inhibition of the RT and PCR
steps. Target-specific primers for cDNA and gDNA were added
to the RT and PCR-amplification steps (Table S2), which also
used modified enzymes (Table S1) that provided more efficient
amplification (Figure 1A). We used an aliquot of the pre-amplified
gDNA and cDNA libraries for targeted NGS of specific cDNA and
gDNA amplicons and another aliquot for whole-transcriptome li-
brary preparation. The libraries used for targeted mutation anal-
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Figure 1. TARGET-Seq: A Method for High-Sensitivity Mutation Detection and Parallel Whole-Transcriptome Analysis from the Same Sin-
gle Cell
(A) Schematic representation of the method (full details are available in STAR Methods and Supplemental Experimental Procedures). In brief, cells were sorted
into plates containing TARGET-seq lysis buffer; after lysis, protease was heat inactivated. RTmix was then added. OligodT-ISPCR primed polyadenylatedmRNA
and target-specific primers primed mRNA molecules of interest. During subsequent PCR, we used ISPCR adaptors to amplify polyA-cDNA, and we used
(legend continued on next page)
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detection of ten mutation hotspots, including SNVs and small in-
dels across both coding and non-coding regions (Figure 1B).
Notably, gDNA amplicons alone achieved a mean 93% bi-allelic
mutation and/or SNV detection (Figure 1C; the variant-calling
pipeline and specific examples of variant calling can be found in
FiguresS2A andS2B, respectively). Importantly,mutational anal-
ysis from rawRNA-sequencing readswas impossible in almost all
cells because of a lack of coverage (Figure S2C), despite the fact
that the mean sequencing depth reached 2.93 million reads/cell.
We next tested whether TARGET-seq would improve the
detection of combinations ofmutations in single cells.Weprofiled
four different mutations in a clonal T cell leukemia diploid cell line
(JURKAT) carrying heterozygous mutations in NOTCH1, RUNX1,
TP53, and PTEN. When we used SMART-seq+, detection of all of
the four mutations within the same single cell was not achieved in
any of the cells analyzed. mRNA targeting detected the four mu-
tations in 38.9% of cells, gDNA targeting in 87.1% of cells, and
TARGET-seq (combined mRNA+gDNA targeting) in 98.4% of
cells (Figure 1D). Therefore, TARGET-seq provides extremely
high sensitivity for the detection of multiple mutations in the
same single cell, and this high sensitivity is essential for reliable
reconstruction of tumor phylogenetic trees.
TARGET-Seq Produces Unbiased Transcriptomic
Readouts from Single Cells
To determine whether TARGET-seq introduces a bias in the sin-
gle-cell whole-transcriptome data, we evaluated its performance
in two cell lines (JURKAT and SET2) and in primary human
HSPCs. Cells clustered by cell type and not by method (Figures
2A and 2B), and there were no significant differences in the
number of genes detected between methods (Figure 2C). The
sequencing quality controls (QCs; Figure S3A), numbers of cells
passing QC (Figure S3B), and transcript coverage (Figure S3C)
were comparable between SMART-seq+ and TARGET-seq,
and there were good correlations of gene expression, including
for genes selected for targeted amplification (Figures 2D, S3D,
and S3E). Similarly, ERCC spike-in controls revealed high corre-
lations between methods (Figures 2E, S3F, and S3G), and cDNA
traces were comparable (Figures S3H–J). These results demon-
strate that TARGET-seq allows accurate mutation detection with
parallel, unbiased, and full-length (Figure S3C) scRNA-seq of the
same single cell.
The Stem Cell Compartment of Patients with MPN is
Genetically and Transcriptionally Heterogeneous
We next applied TARGET-seq to analyze 458 HSPCs in samples
from five patients with myeloproliferative neoplasms (MPN); thetarget-specific cDNA and gDNA primers to amplify amplicons of interest. An aliqu
library and another aliquot for preparing the transcriptome library for scRNA-seq
(B) Frequency with which TARGET-seq detected heterozygous mutations in te
SMART-seq+ and mRNA targeting approaches (n = 376 cells, 2–3 independent
(C) Frequency of detection of heterozygous mutations for the same amplicons as i
bar graph represents mean ± SD.
(D) Frequency of detection of heterozygous mutations in JURKAT cells with SMA
cells), and TARGET-seq (n = 62 cells) when four different mutations (RUNX1,NOTC
experiments. Each slice of the pie chart represents a different combination of
single cell.
4 Molecular Cell 73, 1–14, March 21, 2019samples carried different combinations of JAK2V617F, EZH2,
and TET2 mutations (Tables 1 and S3). Two normal donors
were also included as controls. We isolated LinCD34+ cells
via fluorescence-activated cell sorting (FACS) (Figure S4) and
indexed the cells for CD38, CD90, CD45RA, and CD123 to allow
assessment of clonal involvement in different stem and progen-
itor cell compartments (Majeti et al., 2007). All mutations identi-
fied in total mononuclear cells were also detected in single cells
within the LinCD34+ compartment with TARGET-seq (Table
S3), revealing subclonal mutations with striking inter-patient het-
erogeneity. This allowed us to determine the mutation acquisi-
tion order (Table S3B), which is of importance for MPN biology
(Ortmann et al., 2015). For example, in patient SMD32316 (a
patient with essential thrombocythemia; Tables 1 andS3), we
could determine that a TET2 mutation was acquired after the
JAK2V617F mutation, whereas in patient OX2123 (a patient
with myelodysplastic syndrome [MDS]/MPN overlap; Tables 1
and S3), a TET2 mutation was acquired before a JAK2V617F
mutation. In two patients with a similar JAK2V617F variant allele
frequency (VAF) in bulk mononuclear cells (MNCs), the low per-
centage of ADO that was achieved by TARGET-seq analysis of
single cells revealed that JAK2V617F was heterozygous in
most LinCD34+CD38 cells in patient IF0602 (a patient who
had myelofibrosis [MF] and was receiving treatment with a
JAK1/2 inhibitor; Table 1), and there was a normal distribution
within the different LinCD34+CD38 stem and progenitor frac-
tions (Figure 3A). In contrast, in patient IF0111 (a patient who
had polycythemia vera and was receiving interferon; Table 1), a
lower fraction of clonally involved LinCD34+CD38 cells
were homozygous for JAK2V617F and predominantly had a
CD90+CD45RA+ aberrant phenotype (Figure 3B) that has also
been reported in other myeloid malignancies (Dimitriou et al.,
2016). The ability to reliably distinguish heterozygous versus ho-
mozygous JAK2V617F mutations is of considerable importance
forMPN biology (Li et al., 2014) and also, more broadly, in cancer
because a mutant-allele-specific imbalance is common during
disease progression (Soh et al., 2009).
TARGET-seq analysis uniquely allowed wild-type (WT) HSPCs
to be reliably distinguished from JAK2V617F mutant cells in the
same samples. The analysis revealed the aberrant expression of
biologically relevant genes such as LEPR (Jiang et al., 2008) and
oncogenes such as MYCN, TP53, or PPP2R5A, as well as bio-
logically relevant pathways, including upregulation of hedgehog
(Figure 3D) and Wnt b-catenin (Figure 3F) pathway-associated
transcription (Table S4), in heterozygous (Figures 3C and 3D)
and homozygous (Figures 3E and 3F) JAK2V617F-mutated
HSPCs. HSPCs from patient IF0111 also showed dysregulation
of interferon-associated gene expression, consistent with theot of the resulting cDNA+amplicon mix was used for preparing the genotyping
.
n coding and non-coding regions in cell lines; this approach is compared to
experiments per amplicon; the bar graph represents mean ± SD).
n (B), showing exclusively results from targeted genomic DNA sequencing. The
RT-seq+ (n = 36 cells), mRNA targeting (n = 36 cells), gDNA targeting (n = 62
H1,PTEN, and TP53) in the same single cell were profiled in three independent
mutations, and each color represents the number of mutations detected per
A B
EDC
Figure 2. Unbiased Whole-Transcriptome Analysis of Single Cells with TARGET-Seq
(A) Unsupervised hierarchical clustering of Spearman’s correlations from 180 single cells (JURKAT, n = 56; SET2, n = 86; and HSPC, n = 38); 4,088 highly variable
genes were used. scRNA-seq libraries were generated with SMART-seq+, mRNA targeting, or TARGET-seq as indicated.
(B) tSNE representation of HSPCs, SET2 cells, and JURKAT cells from (A); the same 4,088 highly variable genes as in (A) were used.
(C) Number of detected genes per cell (RPKMR 1) in HSPCs, SET2, and JURKAT cell lines fromSMART-seq+ or TARGET-seq. ‘‘p’’ indicates the Student’s-t-test
p value, and ‘‘ns’’ = non-significance. The boxes represent median and quartiles, and the dots represent the value for each individual cell.
(D) Whole-transcriptome Pearson’s correlation between SMART-seq+ and TARGET-seq ensembles (mean RPKM values per condition) in HSPCs. The
expression values for the genes targeted are highlighted.
(E) Pearson’s correlation between mean ERCC spike-in expression values from SMART-seq+ and TARGET-seq in HSPCs per ERCC spike-in concentration.
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The CD90+CD45RA+ aberrant phenotype was also present at a
similar low frequency in an additional patient with a homozygous
JAK2 mutation (Figure 3G; patient OX4739, an MF patient
receiving JAK1/2 inhibitor treatment). Cells from patient
OX4739 also showed disrupted expression of a number of the
same genes identified in patient IF0111 (Table S4E).
Importantly, this analysis allowed us to identify candidate bio-
markers for JAK2V617F mutations in HSPCs from patients with
an isolated JAK2 mutation (Figure 3H; RXFP1, GAS2, and
WDR86). Interestingly, VWF, a marker of platelet-biased stem
cells (Sanjuan-Pla et al., 2013), was specifically upregulated in
JAK2V617F mutant cells from patients IF0602 and OX4739,
whose disease was characterized by abnormal megakaryocytic
differentiation and MF, but it was not upregulated in JAK2V617F
mutant cells from patient IF0111, who had a polycythemia
phenotype (Figure 3I). These data support the notion that tran-scriptional lineage priming in the HSPC compartment might be
linked to the disease phenotype in MPN.
Distinct Genetic Subclones Present Unique
Transcriptional Signatures
TARGET-seq also uniquely allowed comparison ofWT cells from
patients’ samples and normal controls. Intriguingly, this analysis
established that WT HSPCs from patients with MPN were tran-
scriptionally distinct from normal donor HSPCs (Figure 4A) and
showed enrichment of inflammatory pathways associated with
tumor necrosis factor a (TNFa) and interferon (IFN) signaling
(Figures 3D, 3F, and 4B). These results might indicate the MPN
microenvironment’s effects on the wild-type cells from the
same patient; a similar finding was demonstrated to have clini-
cally predictive value in chronic myeloid leukemia (Giustacchini
et al., 2017). Interestingly, WT HSPCs from patient IF0111, who
was receiving interferon treatment, also showed strong IFNMolecular Cell 73, 1–14, March 21, 2019 5
Table 1. Summary of Donors in the Study, Mutation Status, and Clinical Characteristics
Sample Code Mutation(s) Donor Type Diagnosis Treatment Figures
HD7643 – normal donor – NA Figures 3C–F, 3H, 3I,
4A–E, and S4A
HD7650 – normal donor – NA Figures 3C–F, 3H, 3I, and
4A–E
Aph1 – normal donor – NA Figures 5A–G and 5I–K
HD85 – normal donor – NA Figures 5A–G and 5I–K
SMD32316 JAK2 p.Val617Phe,
TET2 p.Gln958Ter
patient ET aspirin Figures 4A–C and 4E
IF0111 JAK2 p.Val617Phe patient PV pegylated IFN
alpha-2a
Figures 3B, 3E, 3F, 3H, 3I,
4A–C, and 4E
OX4739 JAK2 p.Val617Phe patient myelofibrosis (PMF) ruxolitinib (JAK1 and
JAK2 inhibitor)




patient MDS/MPN overlap with
grade 3 bone marrow
fibrosis
none Figures 4C, 4D and S4B
IF0602 JAK2 p.Val617Phe patient myelofibrosis (PMF) momelotinib (JAK1
and JAK2 inhibitor)
Figures 3A, 3C, 3D, 3H, 3I,
4A–C, and 4E (full length
TARGET-seq); and Figures 5A–K
(3’-TARGET-seq)
IF0155 JAK2 p.Val617Phe patient myelofibrosis (post-ET) anagrelide Figures 5A–K













patient myelofibrosis (PMF) ruxolitinib 10 mg BD
(JAK1 and JAK2
inhibitor)
Figures 5A–C, 6E, 6F, S6, S7C,
S7F, S7I, S7L, and S7O
IF0123 JAK2 p.Val617Phe,
SF3B1p.Lys666Asn
patient myelofibrosis (PMF) ruxolitinib 5 mg BD
(JAK1 and JAK2
inhibitor)




patient myelofibrosis (post-PV) hydroxycarbamide Figures 5A–K, 6C, 6D, S6, S7B,






patient myelofibrosis (PMF) none Figures 5A–G, 6A, 6B, S6, S7A,
S7D, S7G, S7J, and S7M
Additional clinical details are shown in Table S3. PMF, primary myelofibrosis; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm;
ET, essential thrombocythemia; PV, polycythemia vera.
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tion for the transcriptional signatures obtained (Figures 3F
and 4B).
Using the top 2,000 genes identified by random forest analysis
(Figure 4C), we analyzed combinations of mutations and showed
striking clustering of HSPCs of the same genotype from multiple
different patients. HSPCs carrying mutations in epigenetic mod-
ifiers had a highly distinct transcriptomic signature, whereas the
signature of cells carrying only heterozygous JAK2V617F muta-
tions more closely resembled the transcriptome of WT cells (Fig-
ure 4C). EZH2 mutant cells showed enrichment in pathways
such as apoptosis, P53 signaling, hypoxia, and the cell cycle6 Molecular Cell 73, 1–14, March 21, 2019(Figure 4D and Table S4F) previously identified to be correlated
with loss of PRC2 function (Xie et al., 2014) and negative enrich-
ment in genes downregulated upon EZH2 knockdown (Table
S4F). TET2mutant cells also showed enrichment in HSC-related
genes and a negative enrichment in genes downregulated upon
TET2 knockout (Zhang et al., 2016) (Figure 4D and Table S4F).
Moreover, JAK2V617F cells showed dysregulation of STAT5A
targets (Figure 4E and Table S4G). Taken together, these data
demonstrate that TARGET-seq reveals distinct and biologically
relevant molecular signatures of HSPC subclones in MPN and
represents a powerful tool for biomarker and therapeutic target
discovery.
A B
C D E F
G H I
Figure 3. TARGET-Seq Reveals Genetic and Transcriptional Heterogeneity in the Stem-Cell Compartment of Patients with MPN
(A and B) Variant allele frequency of JAK2V617Fmutation (left), as identified by bulk sequencing of total MNCs; proportion of single cells that carry the mutation
(including zygosity) in the Lin-CD34+CD38- compartment (center); and integration of index sorting with mutational information (right) for patients IF0602 (A) and
IF0111 (B).
(C–F) Analysis of disrupted gene expression associated with JAK2V617F mutation in HSPCs. Beeswarm plots show selected differentially expressed genes
between (C) JAK2wild-type (WT) and JAK2V617F-heterozygousmutant cells frompatient IF0602 or (E) JAK2WTand JAK2V617F-homozygousmutant cells from
patient IF0111. Expression values for single cells from two normal donors (NORMAL) are also shown. Each dot represents the expression value for each single
cell; red squares representmean expression values for each group, and boxes represent median and quartiles. Fisher’s test andWilcoxon test p values are shown
on the top of each graph; expressing cell frequencies are shown on the bottom of each bar for each group. Table S4A (patient IF0602) and Table S4C (patient
IF0111) show all significant, differentially expressed genes. (D) GSEA analysis of JAK2WT and JAK2V617F-heterozygous mutant cells from patient IF0602 or (F)
JAK2WT and JAK2V617F-homozygous mutant cells from patient IF0111, as well as cells from normal donors (NORMAL). The heatmap represents –log10(FDR
q-values) for each comparison, for which a FDR q-value cut-off < 0.25 was used; a white color with ‘‘ns’’ represents non-significance. The borders of each square
of the heatmap are colored according to the group in which a particular pathway is enriched. Table S4B (patient IF0602) and Table S4D (patient IF0111) show
results for all significant genesets tested.
(G) Integration of index sorting with mutational information for patient OX4739.
(legend continued on next page)
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Clonal Hierarchies in JAK2 Mutant Myelofibrosis
To increase the throughput of the technique, we adapted
TARGET-seq to allow barcoding and pooling of scRNA-seq li-
braries in a 384-well format in reduced reaction volumes, gener-
ating 30-biased libraries (Table S1C and Figure S5A). Barcodes
could be reliably detected (Figure S5B), sequencing quality met-
rics were in line with other 30-biased scRNA-seq methods (Paul
et al., 2015; Velten et al., 2017) (Figure S5C), and transcript
coverage was 30 biased (Figure S5D). We then analyzed 2,798
cells from a cohort of eight patients with MF and two age-
matched normal donors (Tables 1 and S3). TARGET-seq geno-
typing provided very low dropout rates, in stark contrast to
cDNA genotyping alone (Figures S6A and S6B). This allowed
reconstruction of clonal hierarchies in these patients at unprec-
edented scale and resolution (Figures S6B and S6C and Table
S3). Considerable inter-patient heterogeneity was observed,
and there were both linear and branching patterns of clonal
evolution (Figure S6C). Spliceosome mutations were an early
event in these patients; in contrast, ASXL1 mutations were ac-
quired late, and there were also multiple ASXL1 mutations ac-
quired independently in patient IF0137 (Figures S6B and S6C
and Table S3).
T-SNE analysis using 3,286 highly variable genes showed
distinct clusters of MF HSPCs according to their genotype (Fig-
ure 5A). HSPCs carrying mutations in spliceosome components
or epigenetic modifiers in addition to JAK2 clustered separately
fromWT HSPCs, including WT cells from the same patients, and
were also distinct from cells carrying a JAK2 mutation alone.
TARGET-seq allowed the identification of specific gene expres-
sion associated with certain genetic subclones of HSPCs. For
example, cells carrying mutations exclusively in JAK2 specif-
ically upregulated B4GALT1 (Figure 5B), which is associated
with acquisition of drug resistance in leukemia (Zhou et al.,
2013), and cells with mutations in epigenetic modifiers specif-
ically upregulated PITX1, which has been previously implicated
in leukemogenesis (Nagel et al., 2011). ZFP36 (also known as
TTP), which modulates the interferon-induced inflammatory
response (Sauer et al., 2006), was upregulated in cells carrying
mutations in spliceosome components. Cells carrying mutations
in spliceosome and epigenetic genes upregulated PHB, a pro-
posed therapeutic target in leukemia (Pomares et al., 2016).
MF HSPCs also showed more transcriptional diversity, including
within genetically defined subclones, than WT counterparts (Fig-
ure 5C), suggesting that this transcriptional heterogeneity is not
driven by genetic heterogeneity alone (Figure 5C). Normal donor
HSPCs also clustered separately from WT HSPCs from MF
patients (Figure 5D), an observation similar to that made by
full-length TARGET-seq. Differences between normal donor
and MF WT HSPCs included dysregulation of specific genes
and gene signatures associated with inflammation, as well as(H) Beeswarm plots of selected genes identified as biomarkers of JAK2mutant cel
patients IF0602, IF0111, OX4739 (JAK2 WT and JAK2V617F mutant cells show
quencies are provided at the bottom of each graph for each group.
(I) A Beeswarm plot of VWF expression values across HSPCs for the same patients
single cell; red squares represent mean expression values for each group, and box
are shown on the top of each graph; expressing cell frequencies are shown on t
8 Molecular Cell 73, 1–14, March 21, 2019TNFa and TGFb signaling (Figures 5E and 5F and Table S5).
Furthermore, a number of oncogenes and tumor suppressors
were aberrantly expressed in WT HSPCs from MF patients (Fig-
ure 5G), raising the possibility that these cells might be more
susceptible to malignant transformation and the development
of secondary hematopoietic malignancy.
Specific analysis that compared only JAK2 mutant and WT
cells and used the top 2,000 genes identified by random forest
analysis showed specific clustering of WT, JAK2V617F-
heterozygous, and JAK2V617F-homozygous cells (Figure 5H).
JAK2V617F-heterozygous cells showed enrichment in inflam-
mation-related signatures such as TNFa, TGF b, and IFN
signaling; the G2M checkpoint; and the P53 pathway (Fig-
ure 5I), further validating the pathways previously identified
by full-length TARGET-seq in specific patients (Figure 3).
JAK2V617F-homozygous mutant cells showed enrichment in
WNT b-catenin, hedgehog signaling, and apoptosis, as well
as in inflammation-related signatures (Figure 5I). The distinct
clustering we observed was driven by a number of the same
genes identified by full-length TARGET-seq, e.g., GAS2 and
RXFP1 (Figure 5J and Table S5); we also identified a number
of additional genes (STAT1, CD69, and NFKBIZ [Figure 5J
and Table S5]), some of which were specifically upregulated
in JAK2-homozygous but not JAK2-heterozygous mutant cells
(IL8 and CLEC7A [Figure 5K]).
Transcriptional Differences between Genetic
Subclones within Individual Patients Are Identified with
TARGET-Seq
Finally, we explored whether distinct genetic subclones of
HSPCs in individual patients could be identified with TARGET-
seq. We analyzed three patients with complex clonal hierarchies
(at least three genetic subclones [Figure S6]): patients IF0137
(Figures 6A and 6B), IF0138 (Figures 6C and 6D), and IF0101
(Figures 6E and 6F). Each genetic subclone clustered
separately (Figures 6A, 6C, and 6E) and showed transcriptional
differences driven by pro-apoptotic genes (MCL1 [Figure 6B
and Table S6]), JAK2-STAT signaling (STAT2 [Figure 6D and Ta-
ble S6]), chemokines (CXCL2 [Figure 6D and Table S6), and
genes previously implicated in leukemogenesis (PHB, BCL11A,
and STAG2 [Figures 6B and 6F and Table S6) or drug resistance
(GSTK1 [Figure 6F and Table S6).
We then explored whether the same genetic subclones could
have been identified by common dimensionality reduction or
clustering methods. Dimensionality reduction using highly vari-
able genes (Figures S7A–C) did not identify distinct clustering
patterns associated with genetic subclones in patients IF0137,
IF0138, or IF0101 either when we regressed out the effect of
the cell-cycle phase (Figures S7D–F) or when we specifically
modeled zero inflation (Figures S7G–I) (Pierson and Yau, 2015).
Furthermore, genetic subclones could not be identified with als independently of the patient analyzed. Expression values across HSPCs from
n separately), and two normal donors (NORMAL) are shown; expression fre-
and normal donors as in (H). Each dot represents the expression value for each
es represent the median and quartiles. Fisher’s test andWilcoxon test p values
he bottom of each bar for each group.
Figure 4. TARGET-Seq Reveals Distinct Transcriptional Signatures Associated with the Presence or Absence of Somatic Mutations in
Single HSPCs
(A) tSNE representation of 236 wild-type (WT) HSPCs from the three samples (from patients IF0602, SMD32316, and IF0111) in which WT cells are present, and
cells from two normal donors (donors HD7650 and HD7643); 5,365 highly variable genes were used. Cells from normal donors are colored in gray, and cells from
patients with MPN are colored in orange (patients SMD32316 and IF0602) or red (patient IF0111; patient treated with interferon).
(B) Enrichment of IFN-a (left) or IFN-g (right) signaling gene signatures as a projection of ssGSEA results at the same tSNE coordinates from the cells of the specific
donors or patients shown in (A). Each shape represents a group of donors.
(C) tSNE representation of 448 HSPCs from five patients and two normal controls; the top 2,000 genes as measured by the Gini index from the random forest
analysis were used. Only genotypes present in at least five cells were analyzed. The gene expression matrix was batch- and donor-corrected, and genotypes
were preserved.
(D and E) Enrichment of EZH2-related pathways, TET2-related pathways (D), or the JAK/STAT pathway (E) in cells carrying mutations in these genes compared to
(n = 106) cells from two normal donors. The heatmap represents –log10(FDR q-values) for each comparison, using a FDR q-value cut-off < 0.25. A complete list of
all significant genesets tested can be found in Tables S4F and S4G, and a summary list of all genesets can be found in Table S4H.
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ysis and Parallel RNA Sequencing, Molecular Cell (2019), https://doi.org/10.1016/j.molcel.2019.01.009recently published single-cell K-means clustering method
(SC3) (Kiselev et al., 2017) previously reported to specifically
distinguish genetically distinct subclones of cells (Figures
S7J–L); they also could not be identified with the KNN-based
clustering implemented in the PAGODA2 package (FiguresS7M–O). Distinct genetic subclones from the same patient
were, however, robustly identified by dimensionality reduction
when we used genes that were differentially expressed between
different genetic subclones, the identification of whichwasmade
possible by TARGET-seq (Figure 6).Molecular Cell 73, 1–14, March 21, 2019 9
Figure 5. High-Throughput TARGET-Seq
Identifies Molecular Signatures of Genetic
Subclones in HSPCs from JAK2-V617F
Mutant Myelofibrosis
(A) tSNE representation of 2,734 HSPCs from eight
patients and two age-matched normal donors; the
sampleswere processedwith 30-TARGET-seq, and
3,286 highly variable genes were used for the
analysis. Cells from age-matched normal donors
are colored in light gray (NORMAL). Wild-type (WT)
cells from patients with MF are colored in dark gray
(‘‘WT-P’’). Cells carrying mutations exclusively in
JAK2 are colored in blue (‘‘J’’); those carrying mu-
tations in JAK2 and epigenetic modifiers (TET2 and
ASXL1) are colored in purple (‘‘JE’’); those carrying
mutations in JAK2 and spliceosome components
(SF3B1, SRSF2, and U2AF1) are colored in light
green (‘‘JS’’); and those carrying mutations in
JAK2, spliceosome components, and epigenetic
modifiers are colored in dark green (‘‘JSE’’). The
gene expression matrix was batch- and donor-
corrected, and genotypes were preserved.
(B) Boxplots of representative differentially ex-
pressed genes from JAK2 only (B4GALT1),
JAK2+epigenetic (PITX1), JAK2+spliceosome
(ZFP36), or JAK2+spliceosome+epigenetic (PHB
and ZFP36) genetic subclones. Each dot repre-
sents the expression value for each single cell;
boxes represent median and quartiles, and the
central line represents the median for each group.
Expression frequencies are shown on the bottom
of each bar for each group.
(C) Boxplot of overall Pearson’s correlation of cells
from normal donors and cells from MF-patient
samples; the cells are grouped per donor type
(normal donor orpatient sample; left panel) or by the
genotype groups presented in (A) (right panel). A
Kolmogorov-Smirnov testprovided thesignificance
level for each comparison (***; p value < 0.001).
(D) tSNE representation of 1,066 WT cells from six
patients and two normal donors; 3,436 highly
variable genes were used. The gene expression
matrix was batch-corrected, and the donor effect
was preserved.
(E) tSNE projection (from the same cells as in [D])
representing relative gene expression levels from
selected differentially expressed inflammation-
associated genes in WT cells from patients and
normal donors.
(F) Enrichment of selected pathways in the same WT cells from the same samples as in (D) and (E) from normal donors and patients. A complete list of all
significant genesets tested can be found in Table S5A.
(G) tSNE projection representing relative gene expression levels from selected differentially expressed oncogenes (FOS) and tumor suppressors (ANXA1)
between the same WT cells from patients and normal donors as in (D).
(H) tSNE representation of 769 WT and JAK2-only mutant HSPCs from four patients with MF (patients IF0138, IF0155, IF0157, and IF0602); we used the top
2,000 genes as identified by the Gini index from random forest analysis.
(I) Enrichment of selected HALLMARK and STAT5A pathways from the same cells as in (H), as well as cells from normal donors (NORMAL). A complete list of all
significant genesets tested can be found in Tables S5B and S5C, and specific comparisons for subclones within patients can be found in Table S5D.
(J and K) Analysis of disrupted gene expression associated with JAK2V617F mutation in HSPCs. Boxplots show selected differentially expressed genes
specifically upregulated in JAK2 mutant cells independently of zygosity (J) or exclusively in JAK2-homozygous cells (K). Each dot represents the expression
value for each single cell; boxes represent median and quartiles, and the central line represents the median for each group. Expressing-cell frequencies
are shown on the bottom of each bar for each group. A complete list of all significant differentially expressed genes and associated p values can be found
in Table S5E. The heatmaps are colored according to –log10(FDR q-values) for each comparison, for which an FDR q-value cut-off < 0.25 was used. The
borders of each square of the heatmap are colored according to the group in which a particular pathway is enriched; a white color with ‘‘ns’’ represents
non-significance.
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Figure 6. TARGET-Seq Resolves Genetic
andTranscriptionalHeterogeneity of HSPCs
within Individual Myelofibrosis Patients
(A and B) Distinct transcriptional signatures of
genetic subclones identified by TARGET-seq in
patient IF0137. (A) tSNE representation of 555
cells; 633 differentially expressed genes identified
with ANOVA were used and (B) boxplots of
selected differentially expressed genes between
each genetic subclone from the same cells as in
(A). Genetic subclones carrying JAK2, U2AF1, and
ASXL1 (p897/p910) mutations from patient IF0137
are labeled JAK2-HET+U2AF1-HET+ASXL1-HET
and were analyzed together as indicated. Each
genetic subclone is colored and labeled according
to the legend provided in (A).
(C and D) Distinct transcriptional signatures of
genetic subclones from patient IF0138. (C) tSNE
representation of 243 cells; 418 differentially ex-
pressed genes identified with ANOVA were used.
(D) Boxplots of selected differentially expressed
genes between distinct genetic subclones. Each
genetic subclone is colored according to the
legend provided in (C).
(E and F) Distinct transcriptional signatures of ge-
netic subclones from patient IF0101. (E) tSNE
representation of 320 cells; 500 differentially ex-
pressed genes identified with ANOVA were used.
(F) Boxplots of selected differentially expressed
genes between distinct genetic subclones. Each
genetic subclone is colored according to the
legend provided in (E). Each dot represents the
expression value for each single cell; boxes
represent median and quartiles, and the central
line represents the median for each group. Ex-
pressing cell frequencies are shown on the bottom
of each bar for each group. The list of differentially
expressed genes identified in each patient and
associated p values for each comparison can be
found in Table S6. Only genetic subclones repre-
senting at least 5% of the total cells for each pa-
tient are included in the analysis.
Please cite this article in press as: Rodriguez-Meira et al., Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Anal-
ysis and Parallel RNA Sequencing, Molecular Cell (2019), https://doi.org/10.1016/j.molcel.2019.01.009DISCUSSION
With the advent ofmolecularly targeted therapy in cancer (Longo,
2017), clinical remissions and clonal responses can be readily
achieved in many patients. However, relapse frequently occurs,
and it is often associated with evidence of clonal evolution,
most likely reflecting ITH already present at diagnosis (Smith
et al., 2017) and a differential response to the targeted therapy
in distinct tumor subclones. Therefore, it is crucial to resolve
the clonal heterogeneity of tumors and dissect the transcriptional
heterogeneity associated with the responsive and resistant sub-
clonesof cancer cells. Although scRNA-seqoffers great potential
to resolve the transcriptomic signatures of tumor subclones, up
to now it has not been possible to correlate scRNA-seq data
with mutation analysis because of the lack of coverage for small
indels or point mutations in the scRNA-seq reads, although large
chromosomal aberrations can be detected (Tirosh et al., 2016a).
For example, in a recent study of gliomas, from 22 mutations
analyzed, reads spanning the position of the mutations were de-
tected in 0.4% to 8.7%of the cells (Tirosh et al., 2016b). Althoughmethods for the parallel sequencing of the whole-transcriptome
andwhole-genome of single cells have previously been reported,
these methods are not well suited for high-sensitivity mutation
detection because of high ADO rates (Dey et al., 2015; Macaulay
et al., 2015). Furthermore, these approaches are relatively costly
because of the requirement for whole-genome amplification.
Consequently, up to now, such techniques have not been widely
used for the analysis of cancerous tissues.
We herein report a single-cell RNA sequencing and genotyp-
ing method that provides a simple, easily implementable, and
customizable protocol for high-sensitivity mutation detection
with parallel, unbiased whole-transcriptome analysis. TARGET-
seq has clear advantages above other available scRNA-seq
methodologies and provides improved complexity of scRNA-
seq libraries and a dramatically improved ability to detect
multiple mutations in the same single cell, primarily attributable
to the detection of gDNA variants through modified cell lysis
and high-sensitivity, targeted amplification. The high sensitivity
for bi-allelic detection of mutations provided by our technique
is also of considerable importance as loss of heterozygosity ofMolecular Cell 73, 1–14, March 21, 2019 11
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ysis and Parallel RNA Sequencing, Molecular Cell (2019), https://doi.org/10.1016/j.molcel.2019.01.009a number of different mutations is an important driver of disease
phenotype as well as therapy response (Kharazi et al., 2011).
This is also demonstrated in our analysis of patients with MPN;
this analysis shows clear transcriptional differences between
JAK2-heterozygous and homozygous HSPCs in multiple pa-
tients. TARGET-seq also allowed analysis of the order of acqui-
sition of mutations, which is of importance in cancer biology
(Ortmann et al., 2015). Moreover, TARGET-seq has the advan-
tage of combining scRNA-seq data and mutational analysis
with index sorting, allowing cells to be traced back to canonical
stem and progenitor cell hierarchies. This revealed an aberrant
HSPC phenotype associated with the presence of a JAK2-ho-
mozygous mutation in patients with MPN. Furthermore, the reli-
able identification of WT cells by TARGET-seq allows analysis of
aberrant gene expression in normal tissue-residing cells; such
aberrant expression might reflect cell-extrinsic phenomena.
Such microenvironmental factors might underlie many aspects
of tumor biology and therapy response.
TARGET-seq is adapted to allow both full-length and 30-
biased scRNA-seq approaches. The throughput of the full-length
technique would typically enable the preparation of approxi-
mately 400 cells per week and thousands of cells within a few
months; this amount is in line with the numbers of cells analyzed
in published scRNA-seq tumor datasets (Giustacchini et al.,
2017; Tirosh et al., 2016a, 2016b). This version of the protocol
generates scRNA-seq libraries of high complexity and sensitivity
for detecting low-level expressed genes. Moreover, it allows
analysis of alternative splicing patterns; this is of importance in
cancer biology (David and Manley, 2010), as well as in many
other diseases (Cooper et al., 2009), particularly because com-
ponents of the spliceosome machinery are recurrently mutated
in cancer (Kandoth et al., 2013).
Higher-throughput scRNA-seq techniques are available (Ma-
cosko et al., 2015; Zheng et al., 2017); these typically provide
shallowcoverageof only the 30 or 50 regionof transcripts and lower
molecular capture rates but enable the analysis of larger numbers
of cells. Therefore, we also developed 30-biased TARGET-seq to
allow higher-throughput analysis. 30-TARGET-seq is associated
with shallower coverage than full-length TARGET-seq, reducing
sequencing costs, but it retains high-sensitivity mutation analysis
at the single-cell level. 30-TARGET-seq is mostly automated, and
the process would typically allow 1,000 cells to be processed
per week and tens of thousands to be processed within a few
months, considerably increasing the throughput of the technique.
In a cohort of patients with MF, this approach revealed complex
clonal hierarchies and marked inter-patient variability that was
not apparent frombulk genetic analysis. This alloweddistinct tran-
scriptional signatures of specific genetic subclones and non-
clonally involved WT HSPCs to be characterized, which was not
possible with other computational approaches.
In summary, TARGET-seq is a powerful tool for resolving both
genetic and transcriptional intratumoral heterogeneity. TARGET-
seq also uniquely allows the identification of specific molecular
signatures within genetically distinct subclones of tumor cells.
We expect that this will pave the way for the application of
scRNA sequencing for the definitive analysis of intratumoral het-
erogeneity and the identification and characterization of therapy-
resistant tumor subclones.12 Molecular Cell 73, 1–14, March 21, 2019Limitations
A potential limitation of TARGET-seq is that this approach does
not support mutation discovery and relies on the analysis of
known driver mutations or mutations previously identified by
other discovery-type methods. However, because the lysate is
initially frozen and stored, this will routinely allow for mutational
analysis of the same sample before the subsequent processing
of single cells. Up to now, we have multiplexed primers to detect
a total of 12 different mutations per single cell. Although this will
be adequate for analyzing key driver mutations in many tumors,
for more genetically complex malignancies, a more complex
multiplexing strategy might be required. For very genetically
complex tumors where potentially hundreds of different muta-
tions need to be tracked, a whole-genome and whole-transcrip-
tome approach might be more appropriate (Dey et al., 2015;
Macaulay et al., 2015), albeit at the cost of reduced sensitivity
for the detection of those mutations (Hosokawa et al., 2017;
Wang et al., 2014). In the current study, we have applied this
technique to analyze hematopoietic tumors; however, this
method could be broadly applied to the analysis of a range of
cancers and is a powerful tool for linking transcriptional signa-
tures with genetic tumor heterogeneity.STAR+METHODS
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Cell Lines
K562, MOLT4 and JURKAT cells were obtained from the American Type Culture Collection (ATCC). NALM6 cells were obtained from
the German Collection of Microorganisms and Cell Cultures (DSMZ). SET2 cells were kindly provided by Dr. Jacqueline Boultwood
and Dr. Andrea Pellagatti (Radcliffe Department of Medicine, University of Oxford). All cell lines were maintained in culture in RPMI-
1640 supplemented with 10%Fetal Calf Serum (FCS) and antibiotics. Cell lines were authenticated by targeted sequencing of known
mutations.
Banking and Processing of Human Samples
Patients and normal donors provided written informed consent in accordance with the Declaration of Helsinki for sample collection
and use in research under the INForMeD Study (REC:199833, University of Oxford). Cryopreserved peripheral blood and bone
marrow mononuclear cells (MNCs) were thawed and processed for flow cytometry analysis as previously described (Woll et al.,
2014). Briefly, cryopreserved cells were thawed and 1 mL of FCS was immediately added to each sample. Samples were further
diluted with 8mL IMDM (Iscove’s Modified Dulbecco’s Medium) supplemented with 20% FCS and 10% DNase I (Merck). Samples
were spun down for 10 min at 350 g, washed and spun down again for 10 min at 350 g. A summary of patients and normal donors’
samples used for analysis can be found in Table 1 and Table S3.
Bulk Sequencing of Mononuclear Cells
Bulk genomic DNA from patient samples’ mononuclear cells was isolated using DNeasy Blood & Tissue Kit (QIAGEN) as per man-
ufacturer’s instructions. Targeted sequencing was performed using a TruSeq Custom Amplicon panel (Illumina) consisting of 341
amplicons (56 kb) designed around exons of 32 genes frequently mutated in myeloid malignancies (Hamblin et al., 2014). Library
preparation was performed as per manufacturer’s instructions using 50-250 ng genomic DNA.
Targets were chosen based on the genes/exons most frequently mutated and/or likely to alter clinical practice (diagnostic, prog-
nostic, predictive or monitoring capacity) across a range of myeloid malignancies (e.g., MDS/AML/ MPN), and can be found in the
table below:Gene Exons Covered Gene Exons Covered
ASXL1 12 KRAS 2, 3
ATRX 8, 9, 10, 17-31 MPL 10
CBL 8-9 NPM1 11
CBLB 9-10 NRAS 2,3
CBLC 9-10 PDGFRA 12, 14, 18
CEBPA 1 PHF6 2-10
CSF3R 14-17 PTEN 5-7
DNMT3A 23 RUNX1 3-8
ETV6 1-8 SETBP1 4
EZH2 2-20 SF3B1 14,15
FLT3 14, 15, 20 SRSF2 1
HRAS 2,3 TET2 3-11
IDH1 4 TP53 4-9
IDH2 4 U2AF1 2, 6
JAK2 12,14 WT1 7, 9
KIT 2, 8-11, 13, 17 ZRSR2 1-11Alignment and variant calling were performed in Basespace (utilizing BWA andGATK/Somatic variant caller; Illumina, or SVC) while
filtering and annotation were performed using Variant Studio (Illumina).
Every variant was individually assessed against COSMIC, dbSNP, gnomAD and published literature for frequency in the germline
and acquired state andwhether any data (in vitro or in vivo) suggests its likely pathogenicity. Variants with a population frequency of >
1% were considered polymorphisms. Variants with a population frequency of < 1% but with ethnicity bias and a variant allele fre-
quency close to 50% were also considered polymorphisms.
Any variant passing these criteria and a variant allele frequency cut-off of 5% of the reads (point mutations) or 2% of reads (inser-
tions/deletions longer than 5 bp) was reported as mutated in Table S3 and analyzed for each patient.e4 Molecular Cell 73, 1–14.e1–e8, March 21, 2019
Please cite this article in press as: Rodriguez-Meira et al., Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Anal-
ysis and Parallel RNA Sequencing, Molecular Cell (2019), https://doi.org/10.1016/j.molcel.2019.01.009Fluorescent Activated Cell Sorting (FACS) Staining and Single-Cell Isolation
Single cell FACS-sorting was performed as previously described (Giustacchini et al., 2017), using BD Aria III or BD Fusion I instru-
ments (Becton Dickinson) for 96-well plate experiments and SH800S (SONY) for 384-well plate experiments. Full details are provided
in Supplemental Experimental Procedures. Experiments involving isolation of human hematopoietic stem and progenitor cells
(HSPCs) included single color stained controls (CompBeads, BD Biosciences) and Fluorescence Minus One controls (FMOs). Line-
age-CD34+ cells were sorted and indexed for CD38, CD90, CD45RA and CD123 markers, which allowed us to record the fluores-
cence levels of each marker for each single cell. For samples processed using full-length TARGET-seq in 96 well-plates (Table S3),
HSPCs were stained with the following the antibody cocktail: Lineage-FITC, CD34-APC-e780, CD38-PE-TxRed, CD90-BV421,
CD45RA-PE and CD123-PECy7. For samples processed using 30-TARGET-seq in 384-well plates (Table S3), HSPCs were stained
with the following antibody cocktail: Lineage-PE/Cy5, CD34-PerCp/Cy5.5, CD38-PE-TxRed, CD90-PE, CD45RA-FITC, CD123-
PECy7. The full list of antibodies used for HSPCs immunophenotyping and isolation can be found in Key Resources; 7- aminoacti-
nomycin D (7-AAD) was used for dead cell exclusion. Briefly, single cells directly sorted into 96-well PCR plates containing 4.1-4.2 mL
of lysis buffer or into 384-well plates containing 2.07 mL of lysis buffer . K562 cells were sorted into the lysis buffer described in Table
S1A. JURKAT, MOLT4, NALM6, SET2 and HSPCs (processed using full length TARGET-seq) were sorted into lysis buffers described
in Table S1B. HSPCs processed using 30-TARGET-seq were sorted into the lysis buffer described in Table S1C, using the barcoded
oligodT-ISPCR primers listed in Table S2C (adapted from (Zheng et al., 2018)). Flow cytometry profiles of the HSPC compartment
(Figure S4) were analyzed using FlowJo software (version 10.1).
cDNA Synthesis (RT-PCR)
For K562 cells, RT and PCR steps were performed as described in Table S1A, using 18 cycles of PCR amplification. For JURKAT,
MOLT4, NALM6, SET2 cells and HSPCs (full length TARGET-seq), RT and PCR steps were performed as described in Table S1B,
using 20 cycles of PCR amplification for cell lines and 22 cycles of amplification for HSPCs. For HSPCs processed using
30-TARGET-seq, RT and PCR stepswere performed as described in Table S1C, using 24 cycles of PCR amplification. The sequences
of the primers used in the RT and PCR steps, for whole transcriptome and targeted retrotranscription and cDNA amplification, can be
found in Table S2A and Key Resources Table. Primers were designed to amplify amplicons 250-700 bp long and specificity was
checked against RefSeq and human genome assembly databases using PrimerBlast. mRNA and cDNA primers were designed to
amplify coding regions whereas gDNA primers were designed to bind at least to one intronic region. More information regarding
primer design and validation can be found in the Supplemental Experimental Procedures ‘‘Technical Note: Primer Design and Vali-
dation.’’ After PCR, an aliquot of the cDNA-amplicon mix was used for whole transcriptome library preparation and another aliquot,
for single-cell genotyping library preparation. For full length TARGET-seq, 15 mL from a total of 25 mL of cDNA-amplicon mix were
dilutedwith 11 mL of water, purified using 16 mL of Ampure XPBeads (0.6:1 beads to cDNA ratio; BeckmanCoulter), and resuspended
in a final volume of 8 mL of EB buffer (QIAGEN). For high throughput 30-TARGET-seq, 1 mL from each quadrant of a 384-well plate was
pooled to generate a cDNA pool of barcoded libraries; each cDNA pool was purified twice using Ampure XP beads (0.6:1 beads to
cDNA ratio). The quality of cDNA traces was checked using a High Sensitivity DNA Kit in a Bioanalyzer instrument (Agilent Technol-
ogies). The remaining of the cDNA-amplicon mix was used for subsequent single-cell genotyping or stored at 20 C.
Targeted NGS Single-Cell Genotyping
After RT-PCR, 1.5 mL aliquot from each single cell derived cDNA+ampliconmixwas used as input to generate a targeted and Illumina-
compatible library for single cell genotyping. The preparation of single cell genotyping libraries involves 2 PCR steps (See Supple-
mental Experimental Procedures). In the first PCR step, target specific primers (Table S2B) attached to universal CS1 / CS2 adaptors
(Figure 1, Forward adaptor, CS1: ACACTGACGACATGGTTCTACA; Reverse adaptor, CS2: TACGGTAGCAGAGACTTGGTCT) are
used to amplify the target regions of interest. Target-specific primers were designed to specifically amplify cDNA or gDNA, amplifying
annotated coding regions in the case of cDNA amplicons and at least one intronic region in the case of genomic DNA amplicons. In
the second PCR step (See Detailed Protocol), Illumina compatible adaptors (PE1/PE2) containing 10 bp single-direction indexes
(Access Array Barcode Library for Illumina Sequencers-384, Single Direction, Fluidigm) are attached to pre-amplified amplicons
from the first PCR through CS1/CS2 regions, to generate single-cell barcoded libraries. Amplicons were pooled using a Mosquito
HTS liquid handling platform (TTP Labtech) and pooled amplicons were purified with Ampure XP beads (0.8:1 ratio beads to product;
Beckman Coulter). Purified pools were quantified using Quant-iT Picogreen (Thermo Fisher Scientific) and each pool was diluted to a
final concentration of 4 nM. Pools were further diluted to 10 pM in HT1 buffer prior sequencing.
Up to 384 single cells were sequenced on a MiSeq (Illumina) instrument, with the following sequencing configuration: 151 bp R1,
10 bp index read, 151 bp R2. We used custom sequencing primers for Read1 and Read 2 (500 nM CS1-seq and 500 nM CS2-seq;
See Key Resources) and Index Read (500 nMCS1rc-seq and 500 nMCS2rc-seq; See Key Resources) diluted in 700 mL of HT1 buffer.
Reads were aligned to GRCh37/hg19 using STAR with default settings (version 2.4.2a) and cDNA/gDNA amplicons were separated
into different bam files using a custom pipeline, extracting reads matching the different primer sequences used for targeted PCR
barcoding. This allowed us to obtain independent mutational information from cDNA and gDNA. Variant calling was performed using
mpileup (samtools version 1.1, options–minBQ 30,–count-orphans,–ignore overlaps) and results were summarized with a custom
pipeline (https://github.com/albarmeira/TARGET-seq; Figure S2A). Thresholds for the detection of each amplicon were set based
on non-template controls and thresholds for mutation calling were based on WT controls and customized for each ampliconMolecular Cell 73, 1–14.e1–e8, March 21, 2019 e5
Please cite this article in press as: Rodriguez-Meira et al., Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Anal-
ysis and Parallel RNA Sequencing, Molecular Cell (2019), https://doi.org/10.1016/j.molcel.2019.01.009(1.5%–4% of the reads, representative examples can be found in Figure S2B). Both non-template and WT controls were routinely
processed in parallel to test samples. Importantly, none of the tested mutations were detected in any control cells (n = 874) or blanks
(n = 114) in any of the experiments using the mutational pipeline and cut-offs described, implying that the false positive rate of variant
calling is effectively zero. For experiments involving isolation of HSPCs, QC genotyping was performed as follows: single cells where
one of the targeted amplified genes tested failed to be detected by either gDNA or mRNA were excluded from analysis. Cells for
which cDNA/gDNA mutation analysis showed discrepant readouts were considered heterozygous if one of the molecules (cDNA
or gDNA) gave a heterozygous readout. When one of the molecules gave a homozygous readout and the other gave a WT readout,
cells were also considered heterozygous, although this was a rare event occurring in 0.18% of the amplicons. We considered a cell
homozygous when only the mutant allele was detected at the genomic DNA level and we considered a cell WT when only the WT
allele was detected at the genomic DNA level. We excluded cells in which only the WT or mutant allele were detected at the
mRNA level, but the same gene was not detected at the gDNA level, a rare event occurring in 0.57% of amplicons. Specifically
for JAK2mutation, where we carried out extensive analysis of the data for zygosity, we included an additional ‘‘not determined’’ cate-
gory for cells with mRNA and gDNA JAK2 amplicons in which allele frequency was 0.03 < AF < 0.1 for gDNA (full-length TARGET-seq
dataset), 0.04 < AF < 0.1 for gDNA (30-TARGET-seq dataset) and 0.03 < AF < 0.1 for mRNA (30-TARGET-seq dataset). Not determined
amplicons were excluded from analysis: 36 of 3900 amplicons detected for gJAK2 and 51 out of 1295 amplicons detected for
mJAK2. We required a minimum coverage of 30 reads per amplicon to obtain mutational readouts; the mean coverage per amplicon
is 2641 reads.
Nextera XT Library Preparation for Full-Length Whole-Transcriptome Sequencing
Bead-purified cDNA libraries were used for tagmentation with Nextera XT DNA Kit (Illumina) using one fourth of the original volume
as previously described (Giustacchini et al., 2017). 4nM libraries were diluted to 1.8 pM in HT1 buffer and sequenced on a NextSeq
instrument with 75 bp single-end reads using a NextSeq 500/550 High Output v2 kit (Illumina). HSPCs were sequenced to a mean
sequencing depth of 2.4 M reads.
Nextera XT Library Preparation for 30-Biased Whole-Transcriptome Sequencing
Bead-purified and pooled cDNA libraries were used for tagmentation-based library preparation with Nextera XT DNA Kit (Illumina)
using a custom PCR amplification strategy. Briefly, 1 ng of each barcoded cDNA pool was tagmented as per manufacturer’s
instructions. Subsequently, reaction was stopped and PCR was performed as per manufacturer’s instructions, with the exception
of P5 adaptor, for which 200 nM of a custom P5 adaptor was used (P5_index; See Key Resources). Each indexed pool was bead
purified twice with Ampure XP beads (0.7:1 beads to cDNA ratio). 4nM libraries were diluted to 3 pM in a total volume of 1.3 mL
of HT1 buffer and were sequenced on a NextSeq instrument, using a NextSeq 500/550 High Output v2 kit (Illumina) with a custom
sequencing primer for read1 (P5_SEQ, 900 nM in a total volume of 3 mL of HT1 buffer; See Key Resources) and the following
sequencing configuration: 20 bp R1; 8 bp index read; 64 bp R2. HSPCs were sequenced to a mean sequencing depth of
152,552 reads.
Single Cell Full-Length RNA-Sequencing Data Pre-Processing
RNA-sequencing reads were trimmed for Nextera adaptors with TrimGalore (version 0.4.1) and aligned to the human genome (hg19)
using STAR with default settings (version 2.4.2a). RefSeq gene model was used as the reference for gene expression quantification.
Counts for each RefSeq gene were obtained with FeatureCounts (version 1.4.5-p1; options–primary) and were normalized to reads
per kilobase per million mapped reads (RPKM). Genes with RPKM values less than 1 were considered non-detected (Giustacchini
et al., 2017) and expression values for these genes were converted to zero. We further normalized RPKM expression values into
the log2 scale. QC filtering was performed using the following parameters: percentage of readsmapping in exons > 50%, percentage
of mapped reads > 50% and number of detected genes per cell (RPKM > = 1) > 6000 for JURKAT and SET2 cells, > 5000 for K562
cells and > 1500 for primary HSPCs. For cell lines, we excluded 8 cells after applying these QC filters (5.3%) and for HSPCs,
33 cells (6.1%).
Single Cell 30-Biased RNA-Sequencing Data Pre-Processing
FASTQ files were generated using bcl2fastq (version 2.20) with default parameters and the following read configuration: Y12N*, I8,
Y64N*, in which read1 corresponds to an 8bp cell-specific barcode, index read corresponds to i7 index from each cDNA pool and
read2 corresponds to cDNA sequence. Demultiplexed FASTQ files were trimmed for polyA tails using TrimGalore (version 0.4.1); files
from different lanes were merged together using samtools (version 1.1) and aligned to the human genome using STAR (version
2.4.2a). RefSeq gene model was used as the reference for gene expression quantification. Counts for each RefSeq gene were ob-
tained with FeatureCounts (version 1.4.5-p1; options–primary). Counts were normalized as follows: counts for each single cell were
divided by the total library size for that cell and multiplied by the mean library size of all cells processed (68,412). Genes with normal-
ized count values less than 1 were considered non-detected and expression values for these genes were converted to zero. We
further normalized counts into the log2 scale. QC filtering was performed using the following parameters: library size > 2000 reads;
percentage of reads mapping to the mitochondrial chromosome < 10%; percentage of ERCC < 50% and number of detected genes
per cell (normalized counts > = 1) > 500. We retained 2851 cells after applying these QC filters (81.6%).e6 Molecular Cell 73, 1–14.e1–e8, March 21, 2019
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Bam files from 48 single K562 cells (Figure S1F) or 38 single HSPCs (Figure S1H) were merged using samtools to computationally
create a single cell ensemble. LoFreq software (Wilm et al., 2012) was used for variant calling in the single cell ensemble. Heterozy-
gous regions across the transcriptome (AF > 0.05 of the minor allele, Allele Frequency) were used for variant calling in each
individual cell, requiring a minimum coverage of 10 reads and minimum base quality of 30. A SNV was considered heterozygous
if 0.05 < AF < 0.95 and homozygous if AF < 0.05 or AF < 0.95.
Mutational Analysis from RNA-Sequencing Reads
Variant calling from raw RNA-sequencing reads was performed using mpileup (samtools version 1.1, options–minBQ 30,–count-
orphans,–ignore overlaps) and results were summarized with a custom script (https://github.com/albarmeira/TARGET-seq). Thresh-
olds for the detection of amplicons were set at 30 reads per position (Figure S2C), in line with variant calling guidelines (Sims
et al., 2014).
Dropout Frequency and Library Bias Calculation
The frequency of dropout for a given gene was calculated as the percentage of cells from a specific condition (SMART-seq2 or
SMART-seq+) in which the gene is not detected (RPKM < 1), as compared to the average expression of that gene in K562 bulk sam-
ples (6 replicates of 100 cells each; 3 replicates per chemistry). Library bias was calculated as the ratio between the mean RPKM of
the top 10% expressed genes in the library and the mean RPKM of all genes.
Transcript Coverage
Normalized transcript coverage was calculated using ‘‘geneBody_coverage.py’’ script from RSeQC package (Wang et al., 2012),
using a list of 4040 housekeeping genes obtained from http://rseqc.sourceforge.net/.
Differential Expression Analysis
Differentially expressed genes were identified using a combination of non-parametric Wilcoxon test, to compare the expression
values for each group, and Fisher’s exact test, to compare the frequency of expression for each group, as previously described (Gius-
tacchini et al., 2017). We used log2(RPKM) and log2(normalized counts) matrices, including genes expressed in at least two cells
(when analyzing less than 200 cells; Table S4) or in at least five cells (when analyzing over 200 cells; Tables S5, and S6). P values
were combined using Fisher’s method and adjusted p values were derived using Benjamini & Hochberg procedure. Significant genes
were selected on the basis of adjusted P value < 0.1 and absolute log2(fold change)>0.5. Differentially expressed genes in between
several distinct genetic subclones (Figure 6, and Table S6) were identified using the ‘‘genefilter’’ package in R with analysis of
variance (p value < 0.05). Beeswarm plots from selected genes were generated using ‘‘beeswarm’’ package in R and boxplots
from selected genes were generated using ‘‘ggplot2’’ package in R.
Identification of Highly Variable Genes
We identified variable genes above technical noise by fitting a lowess model of the log2(mean expression level) and coefficient of
variation for each gene. We selected genes with a coefficient of variation above the fitted model and log2(mean expression) > = 0.
Single Cell Clustering and Dimensionality Reduction
T-distributed stochastic neighbor embedding (tSNE) was performed using ‘Rtsne’ package, the implementation of the method in R,
with ‘‘perplexity’’ = 15 for Figures 4A and 4B ‘‘perplexity=20’’ for Figures 2B and 4C. For the analysis of 30-TARGET-seq, similarly to
other high-throughput 30-biased techniques, we first computed a PCA reduction using 50 dimensions, and then used the top thirty
(Figures 5A, 5D, 5E, and 5G), top twenty (Figure 5H) or top five dimensions (Figures 6A, 6C, 6E, and S7A–F) with higher variance to
generate the tSNEplots in Figures 5, 6, and S7, using ‘‘perplexity=20’’ for Figure 5H, ‘‘perplexity=25’’ for Figures 6A, 6C, 6E, and S7A–
F, and ‘‘perplexity=30’’ for Figures 5A, 5D, 5E, and 5G. The number of genes used for each analysis is specified in the legend for each
figure. Zero Inflated Factor Analysis (ZIFA) (Pierson and Yau, 2015) was used to assess transcriptional heterogeneity associated with
the subclonal composition of patients IF0137, IF0138 and IF0101 (Figures S7G–I), performed using highly variable genes with default
parameters. SC3 software (Kiselev et al., 2017) was used to analyze the subclonal composition of patients IF0137, IF0138 and
IF0101, using default parameters and k = 4 for patient IF0137 (as there are four genetically-distinct subclones; Figure S7J) or k =
3 for patients IF0138 and IF0101 (as there are three genetically-distinct subclones; Figures S7K and S7L) with default parameters.
K-Nearest Neighbors clustering integrated in the PAGODA2 package (https://github.com/hms-dbmi/pagoda2) was used to analyze
the subclonal composition of patients IF0137, IF0138 and IF0101 (Figures S7M–O). We calculated a PCA reduction of the batch-
corrected gene expressionmatrix using 50 principal components and 3000 overdispersed genes, computed nearest neighbors using
‘‘cosine’’ distance (k = 15) and identified clusters using ‘‘multilevel community’’ method. We then plotted the tSNE graphs presented
in Figures S7M–O with ‘‘perplexity=25.’’ We observed that transcriptional heterogeneity between genetic subclones within
individual patients was better captured with higher-dimensionality representations, and we therefore represent three tSNE dimen-
sions in Figures 6 and S7.Molecular Cell 73, 1–14.e1–e8, March 21, 2019 e7
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Pearson’s correlation between single cells for each genetic subgroup was calculated using the log2(normalized counts), including
genes expressed in at least five cells (Figure 5C).
Batch Correction
Batch correction was performed using ‘‘limma’’ package in R (Figures 4, 5, 6, and S7). Gene expression matrix was batch and
donor corrected in Figures 4C, 5A, and 5H, while preserving genotypes. Gene expression matrix was batch corrected in Figures
5D, 5E, and 5G, while preserving donor effect. Gene expression matrix was batch corrected in Figures S7A and S7D and plate cor-
rected in Figures S7C and S7F.We used batchNorm function from PAGODA2 package (method = ’’glm’’) to perform batch correction
in Figures S7M and S7O.
Cell Cycle Phase Assignment and Correction
An S-phase andG2M-phase cell cycle score was calculated as themean expression value of a set of S-phase andG2M-phase genes
(Tirosh et al., 2016a) for each cell. S-phase and G2M-phase scores were used to fit a linear model on the normalized and logged gene
expression matrices using ‘‘limma’’ package in R, in order to remove the effect of cell cycle. Cell-cycle corrected matrices were used
as an input for the analysis presented in Figures 5A, 5H, and S7D–F.
Random Forest Analysis
Random forest analysis was performed using ‘randomForest’ package in R (ntree = 2000), trained on the genotypes of single cells.
Only genotypes with at least five cells were included in this analysis. Expression matrix was batch and donor-corrected, and geno-
types were preserved. The top 2000 genes identified by the random forest analysis (MeanDecreaseGini > 0.041 in Figure 4C;
MeanDecreaseGini > 0.045 in Figure 5H) were used for the tSNE representation in Figures 4C and 5H (perplexity = 20). Clustering
of cells was stable when selecting from 500 to 5000 top genes from the random forest analysis.
GeneSet Enrichment Analysis
GSEAwas performed usingGSEA software (http://software.broadinstitute.org/gsea) with default parameters and 1000 permutations
on the phenotype. Gene sets used for the analysis were downloaded from MSigDB or relevant studies (Table S4H). Single Sample
GSEA (ssGSEA) was performed using ssGSEA Projection Module (https://genepattern.broadinstitute.org) with default settings and
combine mode ‘combine.off’. A projection of ssGSEA results is shown in Figure 4B.
QUANTIFICATION AND STATISTICAL ANALYSIS
Unpaired Student t test with Welch’s correction was used for the comparisons in Figures S1A, S1B, S1D, S1E, 2C, and S3A.
Kolmogorov-Smirnov test was used for the comparison of Pearson’s correlations distributions in Figure 5C.
Computational Reconstruction of Clonal Hierarchies
Phylogenetic tree reconstruction for patients with more than one driver mutation was performed using SCITE (Jahn et al., 2016)
with default parameters and ‘‘-r 1 -l 900000 -fd 0.001 -ad 0.01 0.01 -cc 0.’’ We accounted for Loss of Heterozygosity in JAK2 by
introducing the mutational status of each JAK2 allele as separate components of the mutational matrix.
Code Availability
R, Perl and Python scripts used for the analysis are available upon request or accessible at https://github.com/albarmeira/TARGET-
seq. Genotyping pipeline used for analysis of targeted-sequencing data generated by TARGET-seq (SCpipeline) can be downloaded
from https://github.com/albarmeira/TARGET-seq.
DATA AND SOFTWARE AVAILABILITY
Single cell RNA-sequencing data is available at GEO: GSE105454. Single cell targeted sequencing data is available at the NCBI’s
SRA data repository with project number SRA: PRJNA503734 (validation experiments), SRA: PRJNA503736 (full-length TARGETseq
patients’ dataset) and SRA: PRJNA503628 (30-TARGETseq patients’ dataset).
ADDITIONAL RESOURCES
Detailed protocols and primer design technical note: a detailed full-length TARGET-seq, 30-TARGET-seq protocol and a Technical
Note describing primer design and validation is provided as Supplemental Experimental Procedures.e8 Molecular Cell 73, 1–14.e1–e8, March 21, 2019
